Every 8-K that Vyome Holdings, Inc. (HIND) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow HIND and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HIND filings page.
Vyome Holdings, Inc. (HIND) reported leadership changes in its finance organization. The board appointed Jerry Leonard as Chief Financial Officer under a Consulting Agreement with ClearbridgeCFO, LLC, effective September 1, 2026
Vyome will pay ClearBridge a consulting fee of $15,000 per month under an initial one-year term that automatically renews for successive 12‑month periods, subject to termination rights. Robert Dickey notified the board of his voluntary resignation as Interim Chief Financial Officer, effective August 31, 2026, and the company’s consulting agreement with Foresite Advisors, LLC will be deemed terminated the same date.
Vyome Holdings, Inc. (HIND) reported second quarter 2026 results and provided a corporate update centered on its lead VT-1953 program and an expanded immuno-inflammatory pipeline. For the six months ended June 30, 2026, revenue was $58,546 compared with $248,535 in the prior-year period, while operating expenses rose to $2,020,809 from $701,839, leading to an operating loss of $1,992,506 versus $523,185. Net loss was $1,705,204 compared with $602,732 a year earlier.
The balance sheet shows higher liquidity and equity: cash and cash equivalents were $7,887,510 as of June 30, 2026 versus $4,982,333 at December 31, 2025, and total stockholders’ equity increased to $7,311,706 from $3,762,017 as liabilities declined to $1,864,656 from $2,735,160. Management highlights advancement of VT-1953 toward pivotal development, addition of two selective JAK inhibitor assets through an Impetis agreement, and emphasizes a capital structure with no debt, no preferred stock, and no toxic financing instruments.
Vyome Holdings reported first quarter 2026 results and highlighted progress on its clinical pipeline and balance sheet. The company is advancing VT-1953 for malignant fungating wounds and has submitted an application to the FDA for orphan drug designation and proposals for next-stage development planning.
Cash and cash equivalents were $8.8 million as of March 31, 2026, up from $5.0 million at December 31, 2025, with total assets increasing to $10.2 million. Total stockholders’ equity rose to $8.0 million from $3.8 million, and management emphasized having no debt, no preferred stock, and no toxic financing instruments.
For the quarter ended March 31, 2026, Vyome generated revenue of $31,591, down from $198,581 a year earlier, and recorded a net loss of $985,521 versus $293,974 in the prior-year period, driven by higher operating expenses of $1.15 million. The company plans a conference call and webcast on June 3, 2026, to discuss these results.
Vyome Holdings, Inc. reported results of its 2026 annual stockholder meeting and a charter change. Stockholders approved an amendment to reduce common stock authorized for issuance from 300,000,000 to 50,000,000 shares, leaving total authorized capital at 60,000,000 shares, including 10,000,000 preferred shares.
Two Class II directors, Venkat Nelabhotla and John Tincoff, were elected to serve until the 2029 annual meeting. Stockholders also ratified Kreit & Chiu CPA LLP as independent auditors for the year ending December 31, 2026 and approved, on a non-binding advisory basis, the compensation of named executive officers.
Vyome Holdings, Inc., through subsidiary Livechain, Inc. and its unit LICH Inc., entered a Notes Purchase and Exchange Agreement to acquire senior secured convertible notes of Humanyze with aggregate principal of $5,765,000 from Remus Capital.
As consideration, Livechain will issue 211,200,844 shares of its common stock to Remus, equal to 25% of Livechain’s fully diluted common stock immediately before closing, and reserve up to 84,480,338 additional shares (10%) for compensatory grants to key and future employees. After closing, substantially all Humanyze assets and operations are expected to be transferred to the buyer entity in satisfaction of the notes.
The agreement, a related party transaction, was approved by Vyome’s audit committee and board with interested Remus-affiliated directors recusing themselves, and the outside closing date was amended to March 8, 2026. A press release states the Livechain stock issued in the transaction is valued at approximately $325,000.
Vyome Holdings, Inc. furnished an investor presentation highlighting Phase 2 results for VT-1953, a 2% topical gel for malignant fungating wounds. In a 15-patient investigator-sponsored study, VT-1953 significantly reduced malodor by Day 14 versus baseline (p=0.0020) and versus vehicle (p=0.0015), and improved patient-reported malodor impact on quality of life (p=0.0256). Patients also showed statistically significant reductions in malodor and lesion pain on visual analog scales and better composite quality-of-life scores, while exudate did not materially change. VT-1953 was well tolerated with no treatment-emergent adverse events or local reactions reported. Vyome cites a U.S. market opportunity of about $2.2 billion based on ~58,000 new patients per year and a lifetime value per patient of $55,000, and states it is capitalized to fund operations until Phase 3 interim readouts.
Vyome Holdings, Inc. furnished an investor presentation and a related product assessment report about VT-1953, its lead clinical candidate for treating symptoms of malignant fungating wounds. These materials are provided as Exhibit 99.1 under Regulation FD and are not deemed filed for liability purposes.
The company also reported that it issued a press release on January 27, 2026, summarizing key findings from an independent U.S. market assessment, commercial forecast, and valuation analysis for VT-1953, which is attached as Exhibit 99.2. Both exhibits are incorporated by reference and include forward-looking statements about business strategy, capital needs, market potential, and future operating results.
Vyome Holdings, Inc. filed a current report to announce that it released financial results for its third fiscal quarter ended September 30, 2025. On November 18, 2025, the company issued a press release describing these results, which is included as Exhibit 99.1 to this report.
The company notes that the press release and the related information are being furnished, not filed, under securities laws. This means the information carries different legal status and will only be incorporated into other filings if explicitly stated in those future documents.
Vyome Holdings (HIND) reported results of its 2025 Annual Meeting of Stockholders. A quorum of 4,258,856 shares, representing 77.52% of shares outstanding and eligible to vote, was present in person or by proxy.
Stockholders elected Krishna K. Gupta, Shiladitya Sengupta and Stash Pomichter as Class I directors to serve until the 2028 annual meeting. The 2025 Equity Incentive Plan was approved with 3,766,413 votes for, 184,403 against, and 6,600 abstentions, with 301,440 broker non-votes. Stockholders ratified Kreit & Chiu CPA LLP as independent auditor for the fiscal year ending December 31, 2025 with 4,248,216 votes for, 10,081 against, and 559 abstentions.
On a non-binding advisory basis, compensation of named executive officers was approved with 3,945,592 votes for, 11,052 against, 772 abstentions, and 301,440 broker non-votes.
Vyome Holdings, Inc. (HIND) announced it acquired Oculo, Inc. On September 29, 2025, the company reported the purchase of Oculo, an AI startup launched at the Massachusetts Institute of Technology. The announcement was made under Other Events, with a press release furnished as Exhibit 99.1.
This move signals Vyome’s interest in artificial intelligence capabilities originating from MIT’s ecosystem. Additional details are provided in the attached press release referenced in the filing.